Design Cloud

  • Home

  • About Us

    Company Profile HIstory Culture Honor
    • Company Profile

    • HIstory

    • Culture

    • Honor

  • Products

    Cardiovascular series Psychiatry series Hepatobiliary, Gastroenterology Series Respiratory series Anti-infective virus series Other series Large Infusion Series Huabao Tong Series Active Pharmaceutical Ingredient Series
    • Cardiovascular series

    • Psychiatry series

    • Hepatobiliary, Gastroenterology Series

    • Respiratory series

    • Anti-infective virus series

    • Other series

    • Large Infusion Series

    • Huabao Tong Series

    • Active Pharmaceutical Ingredient Series

  • R&D

    Academician Expert Workstation Medical Research and Industry Alliance
    • Academician Expert Workstation

    • Medical Research and Industry Alliance

  • News

    General News Party group dynamics Employee activity
    • General News

    • Party group dynamics

    • Employee activity

  • HR

    Talent Strategy Company recruitment
    • Talent Strategy

    • Company recruitment

  • Contact us

  • 中文版

Image Name

News

  • Home page

General News

Party group dynamics

Employee activity

Public Notice on the Completion and Commissioning of Environmental Protection Facilities for the 980-Ton Per Year Norfloxacin Technology Upgrade Project (Front-End Supplement) at Wanbangde Pharmaceutical Group Co., Ltd.

Date:

18 Nov,2022


Previous page

Good News! Wanbangde Pharmaceutical Group has been named to the "Most Promising Growth Enterprise in China's Pharmaceutical Industry" list for the fourth consecutive year!

Quality Month | Wanbande Pharmaceutical Group’s 5th Annual QCC Selection Event Concludes Successfully

Next page

Related Recommendations

Image Name

2023/06/02

News | Inspection teams from the National Institute for Food and Drug Control, Zhejiang Provincial Institute of Drug Control, and Taizhou Municipal Institute of Drug Control visit Wanbangde for research and guidance

Image Name

2023/06/02

"Building Momentum Gradually | Postdoctoral Research Workstation Accelerates Ahead, Bolstering Pharmaceutical Group’s Scientific Innovation with Fresh Talent!"

Image Name

2023/06/02

Brand Revitalization | The 2023 China Brand Value Evaluation Report Released—Wanbangde Pharmaceutical Group Listed Again!

< 1...272829...78 > proceed page
  • Home

  • About Us

    • Company Profile

    • HIstory

    • Culture

    • Honor

  • Products

    • Cardiovascular series

    • Psychiatry series

    • Hepatobiliary, Gastroenterology Series

    • Respiratory series

    • Anti-infective virus series

    • Other series

    • Large Infusion Series

    • Huabao Tong Series

    • Active Pharmaceutical Ingredient Series

  • R&D

    • Academician Expert Workstation

    • Medical Research and Industry Alliance

  • News

    • General News

    • Party group dynamics

    • Employee activity

  • HR

    • Talent Strategy

    • Company recruitment

  • Contact us

  • 中文版

Image Name

Website Development: China Enterprise DynamicsTaizhou

Business license
浙ICP备10002622号-38